

CROI 2007 Poster Sessions

Time	Monday, February 26
7 am-7 pm	Poster Hall open 7 am to 7 pm Monday: all posters will be available for viewing for the duration of the conference.
1-4 pm	Poster Sessions
	<p>50. Co-Receptors and Tropism (posters 164-182)</p> <p>58. HTLV-I and GB Virus C (posters 247-249)</p> <p>59. Virus-Cell Interactions: Co-Receptor Usage (posters 250-260)</p> <p>61. Accessory Genes (posters 269-271)</p> <p>64. T-Cell Responses and Viral Escape (posters 293-301)</p> <p>67. Genetic Diversity in Early HIV Infection: Incidence and Implications (posters 321-324)</p> <p>69. Cellular and Humoral Immunopathogenesis of Acute HIV Infection (posters 329-339)</p> <p>73. Neuropathogenesis: Experimental Therapeutics (posters 363-368)</p> <p>75. Neuropathogenesis: Clinical Studies (posters 377-380)</p> <p>76. Neurocognitive Dysfunction: Immunologic Mechanisms, Biomarkers, and CNS Drug Penetration (posters 381-388)</p> <p>77. Immunology of CD4 Cells (posters 389-396)</p> <p>78. Immunology of CD8 Cells (posters 397-408)</p> <p>84. T-Cell Vaccine Design: New Vectors and Preclinical Testing (posters 457-468)</p> <p>87. New RTIs and PIs (posters 487-492)</p> <p>88. Targeting CCR5 and CXCR4 (posters 493-496)</p> <p>89. Novel Targets (posters 497-499)</p> <p>92. Clinical Trials of Entry Inhibitors (posters 509-512)</p> <p>103. Clinical Pharmacology in Adults and Children: Issues of Relevance for Developing Countries (posters 575-580)</p> <p>104. NRTI Resistance: New Drugs, Mutations, Mechanisms, and <i>in vitro</i> Dynamics (posters 581-590)</p> <p>107. Novel Mechanisms of Resistance to PIs (posters 601-606)</p> <p>109. Resistance to Entry Inhibitors: Novel Agents, CCR5 Antagonists, and <i>in vitro</i> Dynamics (posters 616-622)</p> <p>115. Transmitted Drug Resistance: Epidemiology and Pathogenesis (posters 648-657)</p> <p>117. Drug Resistance following First-Line ART (posters 661-667)</p> <p>119. Diagnostics Quantification of HIV RNA in Resource-Limited Settings (posters 672-676)</p> <p>121. Genotypic Characterization of the Viral Envelope (posters 680-682)</p> <p>124. Immunology of HIV Infection in Children (posters 690-699)</p> <p>146. ART and Hepatotoxicity (posters 821-824)</p> <p>147. HIV-Associated Nephropathy and other Nephrotoxicity Disease (posters 825-831)</p> <p>148. Tenofovir-Associated Renal Dysfunction (posters 832-835)</p> <p>149. Osteopenia and Osteoporosis (posters 836-838)</p> <p>158. Vaccination against Hepatitis A or B Viruses in HIV-Infected Persons (posters 883-885)</p> <p>159. Acute HCV Infection: Epidemiology and Immunology (posters 886-889)</p> <p>164. Hepatitis Treatment Topics (posters 945-949)</p> <p>168. Morbidity and Mortality of HIV Infection (posters 972-977)</p> <p>169. HIV Transmission Risk (posters 978-984)</p> <p>170. Chemoprophylaxis of Transmission (posters 985-987)</p>

CROI 2007 Poster Sessions

Time	Tuesday, February 27
7 am-9:30 pm	Poster Hall open 7 am to 9:30 pm Monday: all posters will be available for viewing for the duration of the conference.
1-4 pm	Poster Sessions
	<p>51. Intermediaries in Virus-Cell Interaction (posters 183-188)</p> <p>52. Virology: Cellular Co-Factors (posters 189-203)</p> <p>54. Viral Replication (posters 220-234)</p> <p>56. Molecular Epidemiology of HIV: Detection Methods and Tracking of Spread (posters 237-242)</p> <p>63. Impact of HAART on Reservoirs (posters 285-292)</p> <p>65. Correlates of Pathogenesis (posters 302-313)</p> <p>66. Hallmarks of Pathogenic and Nonpathogenic Infection (posters 314-320)</p> <p>74. Neuropathogenesis: Clinical Correlates and Observational Studies (posters 369-376)</p> <p>79. T-Regulatory Cells (posters 409-415)</p> <p>80. Immunology of NK Cells (posters 416-420)</p> <p>81. Viral Envelope, Antibodies, and B Cells (posters 421-431)</p> <p>91. Clinical Trials of RTIs (posters 503-508)</p> <p>94. Predictors of Immunologic Recovery on ART (posters 518-521)</p> <p>95. Predictors of ART Discontinuation, Virologic Response, and Outcomes (posters 522-533)</p> <p>96. HIV Care and Treatment in Resource-Limited Settings: Challenges and Outcomes (posters 534-539)</p> <p>97. Effectiveness of ART in Resource-Limited Settings (posters 540-551)</p> <p>99. Clinical Pharmacology of NRTIs, NNRTIs and Integrase Inhibitors (posters 557-562)</p> <p>100. Clinical Pharmacology of HIV PIs (posters 563-568)</p> <p>101. Clinical Pharmacology of Entry Inhibitors (posters 569-572)</p> <p>105. Novel RTI Resistance Mutations and their Interactions (posters 591-597)</p> <p>106. Resistance and Hypersusceptibility to NNRTIs (posters 598-600)</p> <p>112. Resistance and Viral Fitness: Mechanism and Clinical Impact (posters 633-636)</p> <p>113. HIV Drug Resistance: Prediction of Emergence (posters 637-639)</p> <p>114. Emergence of HIV Drug Resistance in Developing Nations (posters 640-647)</p> <p>127. Pharmacokinetics, Safety, and Efficacy of ART in Infants, Children, and Adolescents (posters 715-721)</p> <p>128. Strategies of ART in Children (posters 722-724)</p> <p>129. Response to ART in Infants, Children, and Adolescents (posters 725-731)</p> <p>130. Predictors of Response to ART in Children (posters 732-736)</p> <p>132. ART Safety during Pregnancy and Post Partum (posters 745-753)</p> <p>133. Risk Factors for MTCT (posters 754-755)</p> <p>134. MTCT and Response to ART during Pregnancy (posters 756-762)</p> <p>135. Outcomes following PMTCT (posters 763-766)</p> <p>136. Factors Associated with Breastfeeding Transmission (posters 767-769)</p> <p>137. Impact of Breastfeeding Cessation (posters 770-771)</p> <p>138. Outcomes following Early Cessation of Breastfeeding (posters 772-775)</p> <p>142. Complications of ART in Resource-Limited Settings (posters 789-793)</p> <p>143. ART-Associated Toxicities in Resource-Limited and Developed Countries (posters 794-799)</p> <p>144. Lipoatrophy and Mitochondrial Dysfunction (posters 800-806)</p> <p>145. Cardiovascular, Lipid, and Metabolic Complications of ART (posters 807-820)</p> <p>150. OIs: Incidence, Pathogenesis, and Treatment (posters 839-845)</p> <p>154. Invasive Bacterial Infections (posters 864-866)</p> <p>156. Incidence of Cancer in HIV Infection (posters 874-875)</p> <p>157. Lymphoma and Kaposi's Sarcoma Pathogenesis and Impact of Treatment (posters 876-882)</p> <p>162. Impact of HBV or HCV on Disease Progression in HIV-Infected Persons (posters 919-929)</p> <p>163. Effects of ART on Liver Disease in HBV or HCV Co-Infected Persons (posters 930-944)</p> <p>166. Behavioral Aspects of HIV Infection and Diagnosis (posters 963-966)</p> <p>167. HIV Transmission Factors (posters 967-971)</p> <p>171. Microbicides: Pre-clinical, <i>in vitro</i>, <i>ex vitro</i>, and Modeling Studies (posters 988-1000)</p>

CROI 2007 Poster Sessions

Time	Wednesday, February 28
7 am-6 pm	Poster Hall open 7 am to 6 pm Monday : all posters will be available for viewing for the duration of the conference.
1-4 pm	Poster Sessions
	<p>53. Cellular Restrictions (posters 204-219)</p> <p>55. Genetic Analysis of Viral Diversity (posters 235-236)</p> <p>57. Virology: Zoonotic Infections (posters 243-246)</p> <p>60. Cellular Factors Impacting Virus Replication (posters 261-268)</p> <p>62. Cellular Reservoirs and Viral Persistence (posters 272-284)</p> <p>68. Viral Pathogenesis of Primary Infection (posters 325-328)</p> <p>70. Diagnosis of Acute and Chronic HIV Infection (posters 340-345)</p> <p>71. ART during Acute Infection (posters 346-349)</p> <p>72. Neuropathogenesis: Virology and Immunology (posters 350-362)</p> <p>82. Antigen Presenting Cells and Toll-Like Receptors (posters 432-437)</p> <p>83. Special Issues in Immunopathogenesis (posters 438-456)</p> <p>85. Vaccines: Neutralizing Antibodies and Clinical Trials (posters 469-476)</p> <p>86. Immune-Based Therapies (posters 477-486)</p> <p>90. Targeting HIV Reservoirs (posters 500-502)</p> <p>93. Treatment Interruptions and Simplification (posters 513-517)</p> <p>98. Pharmacogenomics (posters 552-556)</p> <p>102. Drug Interactions (posters 573-574)</p> <p>108. Predicting Virologic Response to PIs (posters 607-615)</p> <p>110. HIV Integrase: Natural Variation and Resistance to Inhibitors (posters 623-627)</p> <p>111. Drug Resistance: Diagnostics and Special Compartments (posters 628-632)</p> <p>116. Drug Resistance: Special Populations and Outcomes (posters 658-660)</p> <p>118. Diagnostics Detection of HIV Infection in Neonatals (posters 668-671)</p> <p>120. Diagnostics Detection of Viruses and Antibodies in Bodily Fluids other than Blood (posters 677-679)</p> <p>122. Strategies for Diagnosis of HIV Infection in Infants and Children (posters 683-687)</p> <p>123. Risk of HIV Infection in Youth (posters 688-689)</p> <p>125. Risk of Disease Progression in HIV-Infected Children (posters 700-703)</p> <p>126. Complications of HIV Infection and ART in HIV-Exposed and -Infected Children (posters 704-714)</p> <p>131. Pharmacokinetics of ARVs in Pregnancy and Delivery (posters 737-744)</p> <p>139. Outcomes and Complications of HIV Infection in Women (posters 776-779)</p> <p>140. HIV Infection in Women: Special Issues (posters 780-784)</p> <p>141. Pharmacokinetics of ARVs in Women (posters 785-788)</p> <p>151. HIV-Related TB: Incidence and Strategies for Prevention of Active Disease (posters 846-852)</p> <p>152. HIV-Related TB: Diagnosis, Treatment, and Pathogenesis (posters 853-858)</p> <p>153. TB and HIV Co-Infection: Detection and Treatment Challenges (posters 859-863)</p> <p>155. HIV and Sexually Transmitted Infections (posters 867-872)</p> <p>160. Antiviral Chemotherapy of HCV Infection (posters 890-907)</p> <p>161. Noninvasive Assessment of Liver Damage (posters 908-918)</p> <p>165. Issues in Detection of HIV Infection (posters 950-962)</p>